Impactiviti Daily 103009

TODAY’S NEWS
FTC says “yes” to Merck-Schering merger.
AstraZeneca’s experimental drug Brilinta may not get along well with aspirin: AstraZeneca Plc is looking into whether greater use of aspirin reduces the effectiveness of its experimental clot-busting medicine Brilinta, which analysts had estimated would bring in $1 billion a year…more Plus, AZ agrees to a $520M fine in [...]

Read Full Post »

Impactiviti Daily 102909

 
TODAY’S NEWS
Roche: Our upcoming diabetes drug works better than Byetta. Will be interesting to see the full set of data.
AstraZeneca’s experimental oncology drug Zactima: let’s step back for a time-out.
Genta: time to give up on Genasense? Not sure this horse is ever going to gallop.
RECOMMENDED
Compliance Training. Impactiviti’s partner network includes solutions providers for every [...]

Read Full Post »

Two Thumbs Up: ePatient Connection Conference

I was in downtown Philadelphia earlier this week for the inaugural ePatient Connection 2009 conference, a first-time event by the relatively new Kru Research (headed up by Kevin Kruse). I’ve known Kevin for years through our mutual work in pharma training/eLearning, but this was his first venture into organizing a conference.
Count me impressed.
Unlike last week’s [...]

Read Full Post »

Impactiviti Daily 102809

Note: Impactiviti Daily is going to be published somewhat irregularly over the next couple of weeks, as we’re in the heart of “conference” season and I’m attending/speaking at several events over the next month. We’ll do our best to keep you updated!
TODAY’S NEWS
FDA approves Arzerra (from GSK) for last-ditch treatment of CLL (cancer)
Boehringer-Ingelheim gets additional [...]

Read Full Post »

Disease Guilt

I’m enjoying a two-day conference on the empowered health consumer (ePatients 2009) – one of the most enjoyable aspects being hearing directly from people with diseases (such as diabetes) who are living out the management of their conditions on-line.
I was taken aback late yesterday when one of the diabetes bloggers mentioned the constant GUILT that [...]

Read Full Post »

I Was There (Digital Pharma 2009)

You know how everyone wants to claim that they were physically present for earth-shattering historical events?
Well, in 20 years or so, pharma people across the globe will all claim that “I was there!” for Digital Pharma 2009.
OK, that’s a bit of hyperbole. But I WAS there this week, and so it’s time for a re-cap. [...]

Read Full Post »

If I were Directing Social Media at Pfizer…

Today, Pfizer is in the news for completing its acquisition of Wyeth. It’s a big day for the company, marked with the standard press releases and all the usual communications methods.
On Twitter? One boring tweet with a press release link.
The fact is, Pfizer has not been very aggressive with their social media presence. While they [...]

Read Full Post »

Impactiviti Daily 101609

Note: Impactiviti Daily is going to be published somewhat irregularly over the next 4 weeks, as we’re in the heart of “conference” season and I’m attending/speaking at several events over the next month. We’ll do our best to keep you updated!
TODAY’S NEWS
Pharma sales reps should be paid overtime? This is getting interesting – Novartis sales [...]

Read Full Post »

Pfizer changes logo after Wyeth acquisition?

I haven’t seen any formal announcement, but if you go to the Pfizer home page or look at this news release, you can see that (apparently) Pfizer has updated their company logo.

The weighting on the letters is more even, the color is lighter – many of the old logo elements are the same, but there [...]

Read Full Post »

Impactiviti Daily 101409

TODAY’S NEWS
B-I gets (European) clearance for extended-release Parkinson’s drug formulation.
Avodart + Flomax – a good combo for your prostate? – The drug was shown, when given with tamsulosin, to have benefits for men with prostate enlargement. In the four-year CombAT study Avodart (dutasteride) and tamsulosin together showed a 66% reduction in the risk of acute [...]

Read Full Post »